Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) EBITDA (2016 - 2025)

Fate Therapeutics' EBITDA history spans 14 years, with the latest figure at -$32.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 38.52% year-over-year to -$32.4 million; the TTM value through Dec 2025 reached -$136.5 million, up 26.63%, while the annual FY2025 figure was -$136.5 million, 26.63% up from the prior year.
  • EBITDA reached -$32.4 million in Q4 2025 per FATE's latest filing, down from -$32.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$17.7 million in Q1 2023 to a low of -$83.4 million in Q3 2022.
  • Average EBITDA over 5 years is -$48.9 million, with a median of -$45.9 million recorded in 2021.
  • Peak YoY movement for EBITDA: skyrocketed 73.93% in 2023, then crashed 172.81% in 2024.
  • A 5-year view of EBITDA shows it stood at -$69.3 million in 2021, then grew by 20.7% to -$55.0 million in 2022, then rose by 20.66% to -$43.6 million in 2023, then decreased by 20.9% to -$52.7 million in 2024, then soared by 38.52% to -$32.4 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's EBITDA are -$32.4 million (Q4 2025), -$32.2 million (Q3 2025), and -$34.2 million (Q2 2025).